Tuesday, 10 April 2018 20:20

Using moxa on St 36 zusanli to reduce chemotherapy-induced pancytopenia: a feasibility study - Beverley de Valois

Moxa on St 36 has been used for centuries in Asian medicine for strengthening the body, improving health, nourishing blood and supporting the immune system. This has implications for use during active cancer treatment, particularly chemotherapy (which destroys blood cells as well as cancer cells) to reduce toxicities and improve outcomes.

Building on published clinical observations by Staebler (2009) and Davies (2013), this study is the first step in investigating whether application of moxa on ST 36 reduces chemotherapy-induced cytopenia (neutropenia, anaemia, thrombocytopenia). It explores the feasibility of conducting this research within the NHS, teaching cancer patients undergoing chemotherapy to self-administer moxa on St 36 daily throughout the duration of their treatment. The primary outcome is adherence to daily self-administered moxibustion (measured by daily diaries. Secondary measures include blood counts, adherence to planned chemotherapy schedule, health-related quality of life, and adverse events of moxibustion. Acceptability of using moxa to cancer patients and their healthcare professionals is also explored.

In this first presentation of the study results, the Principal Investigator Beverley de Valois will discuss the challenges of introducing a novel intervention into the NHS and some of the surprises that emerged during this study funded by the British Acupuncture Council.